Neuros Medical has announced the results from their long term pilot study. The study evaluated the company’s high frequency electrical nerve block technology which focused on patients afflicted with chronic amputation pain.
According to a company release, results indicated that seven out of nine study subjects reported significant pain reduction (50%≥) observed for up to 12 months of evaluation. The study demonstrated no safety issues over the treatment period.
Study subjects reported an average pain score reduction of six to one (an 83% pain reduction) based on a 0 to 10 Numerical Rating Scale. Significant pain reduction was reported in 91% of all treatment sessions. In addition, more than half of the subjects discontinued their narcotic pain medication use during the study, according to the release.
The study was led by Amol Soin of the Kettering Health Network Innovation Center and the Ohio Pain Clinic, USA. “It is outstanding to see the Neuros technology continue to provide such significant pain relief for patients,” said Soin. “It is also very promising to see the safety results confirmed over a larger set of patients for such an extended period of time.”
Jon J Snyder, president and CEO of Neuros Medical, said: “We are extremely pleased with the opportunity to improve the lives of amputees. Our study results have shown that study subject pain scores are consistently and significantly reduced over this long term evaluation. This provides further clinical evidence of the strong potential of our treatment for patients suffering from chronic pain. We look forward to sharing more details at the upcoming International Neuromodulation Society’s [INS] 11th World Congress in Berlin, Germany, 8–13 June.”
